Investment

Barcelona, March 26th , 2021 INBRAIN Neuroelectronics is a spin-off company from Graphene Flaship partners’ the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, established in 2019 in the intersection between Medtech, DeepTech and Digital Health. INBRAIN has the mission to decode brain signals into medical solutions by developing intelligent neuroelectronic therapies based on graphene technology for application in patients with Epilepsy, Parkinson’s and other brain related disorders. In…

https://mybinxhealth.com/news/binx-health-collaborates-with-amazon-business-for-delivery-of-covid-19-sample-collection-kits-to-u-s-businesses-schools-and-governments/

http://www.peptomyc.com/green-light-by-the-aemps-to-start-clinical-trials-with-omo-103/

-Former LabCorp Chairman and CEO joins binx board during period of rapid growth- BOSTON, MA, [DATE]– binx health today announced the addition of David P. King to its Board of Directors. Mr. King served for nearly 13 years as Chairman and CEO of LabCorp, where he spearheaded the company’s transformation from a pure-play clinical laboratory into a global leader in life sciences, tripling the size of the company to more…

Barcelona, Spain, March 5th, 2021: Ona Therapeutics, a company focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today that it has appointed Dr. Mark Throsby as independent board member of its Board of Directors. Dr. Throsby is a proven senior executive with more than 20 years of experience in the pharma & biotech industry and has led multiple drug discovery programs from conception to…

https://accure.health/accure-therapeutics-enrols-first-patient-in-phase-ii-clinical-trial-on-acute-optic-neuritis-with-lead-candidate-act-01/

https://www.asebio.com/actualidad/noticias/asebio-une-las-principales-gestoras-especializadas-de-capital-riesgo-para

https://mybinxhealth.com/news/binx-health-enters-into-distribution-agreement-for-national-launch-of-the-fda-cleared-binx-io/

https://accure.health/accure-therapeutics-publishes-pivotal-preclinical-efficacy-study-in-epilepsy/

https://www.sanifit.com/sanifit-granted-orphan-drug-designation-by-the-fda-for-snf472-for-the-treatment-of-peripheral-arterial-disease-in-patients-with-end-stage-kidney-disease/